.
MergerLinks Header Logo

Announced

Completed

KKR-backed Biosynth Carbosynth completed the acquisition of Pepscan.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Netherlands

Cross Border

Biotechnology

peptide-based products

Completed

Private

Majority

Acquisition

Single Bidder

Private Equity

biotechnology company

Friendly

Synopsis

Edit

KKR-backed Biosynth Carbosynth, a supplier of critical products and services to the life sciences industry, completed the acquisition of Pepscan, an expert provider of peptide-based products & services. Financial terms were not disclosed. "We are thrilled to be able to bring Pepscan’s outstanding peptide expertise into the group and form our new, global Peptide division. This allows us to continue to simplify the supply chains for our customers across life sciences, pharma and diagnostics, so they deal with one organization for all of their needs. Pepscan is known for their scientific knowledge and expertise and have a complementary set of manufacturing to those we have already, including GMP capabilities, so it was a perfect fit," Urs Spitz, Biosynth CEO and President.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US